Pembrolizumab vs Pembrolizumab berahyaluronidase alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02142738 · Phase 3 · completed

The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).

Next expected readout: November 2026 · NCT06545331 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)

Result source: NCT02142738

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05722015 · Phase 3 · active, not recruiting

Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.

Next expected readout: December 2029 · NCT07190248 (registry estimate)

Reported efficacy

Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)

Result source: NCT05722015

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPembrolizumabPembrolizumab berahyaluronidase alfa
PFS, median8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results
—Trial running · NCT05722015
OS, median15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results
—Trial running · NCT05722015
ORR47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752
Duration of response, median11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results
—Trial running · NCT05722015

PFS, median

Pembrolizumab
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015

OS, median

Pembrolizumab
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015

ORR

Pembrolizumab
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474
Pembrolizumab berahyaluronidase alfa
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752

Duration of response, median

Pembrolizumab
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Pembrolizumab: 4 of 4 rows · Pembrolizumab berahyaluronidase alfa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPembrolizumabPembrolizumab berahyaluronidase alfa
Dropout rate
n/a: no completion milestonePembrolizumaba
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
54%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
58.8%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
n/a: no completion milestone
NCT02775435 · Phase 3 · combination
n/a: no completion milestone
NCT02220894 · Phase 3
n/a: no completion milestone
NCT02504372 · Phase 3
89.3%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
33%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
0%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02864394 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT03850444 · Phase 3 · registry result, not featured evidence
2.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
90.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
80.7%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
89.2%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
94.4%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02955758 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
3.2%
NCT02733159 · Phase 2 · registry result, not featured evidence
87.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
86.4%
NCT03087760 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneb
NCT05722015 · Phase 3 · combination
show 1 more result
n/a: no completion milestone
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
8.4%Pembrolizumaba
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
4.9%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
6.7%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
11.5%
NCT02775435 · Phase 3 · combination
19.9%
NCT02220894 · Phase 3
—
NCT02504372 · Phase 3
—200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
—Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
3.1%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
—
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
—
NCT02864394 · Phase 3 · registry result, not featured evidence
12.5%
NCT03850444 · Phase 3 · registry result, not featured evidence
—
NCT03634241 · Phase 2 · registry result, not featured evidence
—Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—
NCT02955758 · Phase 2 · registry result, not featured evidence
—Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02733159 · Phase 2 · registry result, not featured evidence
12.3%
NCT03004183 · Phase 2 · registry result, not featured evidence
11.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
—
NCT03087760 · Phase 2 · registry result, not featured evidence
—b
NCT05722015 · Phase 3 · combination
show 1 more result
—
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
—Pembrolizumaba
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
51.3%Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
16.7%Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
38.8%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
36.6%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
57.5%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
22.2%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
46%
NCT02775435 · Phase 3 · combination
41%
NCT02220894 · Phase 3
24.5%
NCT02504372 · Phase 3
20.7%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
35%Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
37.7%Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7.7%Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
23.4%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
50%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
100%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
54.7%Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
35.1%
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
53.8%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
36%
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
36.2%
NCT02864394 · Phase 3 · registry result, not featured evidence
32.8%
NCT03850444 · Phase 3 · registry result, not featured evidence
7.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
9.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
20%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60.8%800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
46.7%200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
52.5%Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
47.6%Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
37.8%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
47.4%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
54.1%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
25%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
36%
NCT02955758 · Phase 2 · registry result, not featured evidence
58.9%Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.1%Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
85%
NCT02733159 · Phase 2 · registry result, not featured evidence
51.8%
NCT03004183 · Phase 2 · registry result, not featured evidence
40.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
45.5%
NCT03087760 · Phase 2 · registry result, not featured evidence
39%b
NCT05722015 · Phase 3 · combination
show 1 more result
42.9%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
diarrhoea 26.6%
dyspnoea 26.6%
fatigue 24%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 42 more results
upper respiratory tract infection 33.3%
constipation 16.7%
decreased appetite 16.7%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
10 mg/kg
fatigue 25.7%
decreased appetite 23.3%
dyspnoea 23%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
2 mg/kg
decreased appetite 30.7%
fatigue 30.1%
nausea 25.7%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
nausea 57.3% (placebo 51%)
anaemia 45.9% (placebo 45%)
fatigue 42.7% (placebo 39.6%)
NCT02578680 · Phase 3 · combination
abdominal pain 22.2% (placebo 6.4%)
cough 22.2% (placebo 30.7%)
diarrhoea 22.2% (placebo 20.3%)
NCT02578680 · Phase 3 · combination
anaemia 53.2% (placebo 49.6%)
alopecia 46% (placebo 37.5%)
nausea 36.3% (placebo 32.1%)
NCT02775435 · Phase 3 · combination
decreased appetite 17%
cough 16.8%
dyspnoea 16.5%
NCT02220894 · Phase 3
weight increased 22.8% (placebo 28.9%)
pruritus 21.6% (placebo 12.7%)
hypothyroidism 20.7% (placebo 4.6%)
NCT02504372 · Phase 3
200 mg IV Q3W
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
anaemia 36.2%
nausea 24%
fatigue 17.2%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 37.7%
nausea 19%
aspartate aminotransferase increased 16.6%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 14.3%
covid-19 14.3%
headache 14.3%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 15.4%
cough 15.4%
productive cough 15.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 38.4%
nausea 30.9%
neutropenia 23.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anemia 75%
cough 75%
abdominal pain 50%
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03867175 · Phase 3 · registry result, not featured evidence
hypertension 41.4%
diarrhoea 40.9%
hypothyroidism 35.4%
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
anaemia 40.4% (placebo 44.7%)
nausea 39.2% (placebo 43.5%)
neutrophil count decreased 36.7% (placebo 45.9%)
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
alopecia 78.5%
white blood cell count decreased 78.5%
neutrophil count decreased 76.9%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
nausea 72% (placebo 53.3%)
constipation 64% (placebo 73.3%)
decreased appetite 56% (placebo 60%)
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
anaemia 33.3%
aspartate aminotransferase increased 21.6%
cough 21.6%
NCT02864394 · Phase 3 · registry result, not featured evidence
anaemia 30.5%
cough 23.4%
pyrexia 22.7%
NCT03850444 · Phase 3 · registry result, not featured evidence
fatigue 45%
investigations 25%
alanine aminotransferase increased 20%
NCT03634241 · Phase 2 · registry result, not featured evidence
anaemia 42.9%
diarrhoea 33.3%
fatigue 28.6%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
asthenia 40%
blood creatinine increased 40%
blood urea increased 40%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
800 mg
diarrhoea 29.4%
fatigue 21.6%
alanine aminotransferase increased 19.6%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
200 mg
pyrexia 23.3%
constipation 20%
decreased appetite 20%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
hypertension 52.5%
diarrhoea 45%
hypothyroidism 36.3%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
pruritus 29.3%
cough 22%
fatigue 20.7%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
fatigue 29.7%
pruritus 29.7%
nausea 24.3%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
asthenia 34.2%
dyspnoea 34.2%
cough 29.8%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
asthenia 21.6%
anaemia 18.9%
cough 18.9%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 36.1%
dyspnoea 36.1%
cough 30.6%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
nausea 24%
decreased appetite 20%
worsening abdominal pain 20%
NCT02955758 · Phase 2 · registry result, not featured evidence
anaemia 39.3%
fatigue 34.8%
alopecia 31.3%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
nausea 52%
asthenia 40.2%
anaemia 32.4%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
fatigue 60%
dyspnea 48.3%
cough 35%
NCT02733159 · Phase 2 · registry result, not featured evidence
fatigue 21.4%
nausea 12.5%
back pain 10.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
fatigue 56.5%
hypoalbuminemia 44.9%
hyponatremia 39.1%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
esophagitis 36.4%
fatigue 36.4%
hypothyroidism 22.7%
NCT03087760 · Phase 2 · registry result, not featured evidence
b
anaemia 58.2%
neutropenia 41.8%
leukopenia 29.5%
NCT05722015 · Phase 3 · combination
show 1 more result
neutropenia 46.4%
anaemia 42.9%
constipation 39.3%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 42 of these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

PFS Rate at 6 62.1% (n=154) vs 50.3% (n=151) SOC Chemotherapy @ 24wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
OS Rate at 12 70.3% (n=154) vs 54.8% (n=151) SOC Chemotherapy @ 48wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.7 vs 8.5 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
10.4 vs 8.5 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
PFS 4 vs 4 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
3.9 vs 4 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
ORR 18.5% (n=346) vs 9.3% (n=343) Docetaxel10 mg/kg
responder rate · % of participants
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
18% (n=344) vs 9.3% (n=343) Docetaxel2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Duration of Response NA vs 6.23 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
NA vs 6.23 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
PFS 8.8 vs 4.9 placebo months
time to event · months
NCT02578680 · Phase 3 · combination
show 10 more results
6.4 vs 4.8 placebo months
NCT02775435 · Phase 3 · combination
6.5 vs 6.4 Chemotherapy months @ 191wk
NCT02220894 · Phase 3
6.2 vs 6.7 Chemotherapy months @ 191wk
NCT02220894 · Phase 3
5.4 vs 6.6 Chemotherapy months @ 191wk
NCT02220894 · Phase 3
5.6 vs 4.2 Docetaxel months
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
5.6 vs 5.5 placebo months
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
4 vs 2.5 Docetaxel months
NCT02864394 · Phase 3 · registry result, not featured evidence
3.3 vs 3 Docetaxel months
NCT02864394 · Phase 3 · registry result, not featured evidence
2.5 vs 2.4 Pembrolizumab + MK-4830 months
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
4.5 vs 5.2 Standard of Care (Inv. Choice) months
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
Overall Survival NA vs 11.3 placebo months
time to event · months
NCT02578680 · Phase 3 · combination
show 9 more results
15.9 vs 11.3 placebo months
NCT02775435 · Phase 3 · combination
20 vs 12.2 Chemotherapy months @ 191wk
NCT02220894 · Phase 3
18 vs 13 Chemotherapy months @ 191wk
NCT02220894 · Phase 3
16.4 vs 12.1 Chemotherapy months @ 191wk
NCT02220894 · Phase 3
11.3 vs 12 Docetaxel months
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
15.9 vs 14.7 placebo months
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
12.3 vs 10.9 Docetaxel months
NCT02864394 · Phase 3 · registry result, not featured evidence
12.9 vs 10.6 Docetaxel months
NCT02864394 · Phase 3 · registry result, not featured evidence
14.5 vs 11.6 Standard of Care (Inv. Choice) months
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 11.2 vs 7.8 placebo months
time to event · months
NCT02578680 · Phase 3 · combination
show 6 more results
7.7 vs 4.8 placebo months
NCT02775435 · Phase 3 · combination
6.9 vs 6.8 Docetaxel months
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
6.3 vs 5.6 placebo months
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
16.6 vs 6.4 Docetaxel months
NCT02864394 · Phase 3 · registry result, not featured evidence
16.6 vs 6.3 Docetaxel months
NCT02864394 · Phase 3 · registry result, not featured evidence
12.9 vs 5.6 Standard of Care (Inv. Choice) months
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
Disease-free Survival 53.8 vs 43 placebo months
time to event · months
NCT02504372 · Phase 3
show 3 more results
67 vs 47.6 placebo months
NCT02504372 · Phase 3
58.7 vs 42.8 placebo months
NCT02504372 · Phase 3
53.6 vs 42 placebo months @ 295wk
NCT02504372 · Phase 3
PFS 7.1 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
8.3 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7 months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
2.6 months
NCT02955758 · Phase 2 · registry result, not featured evidence
29 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.3 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
4.39 months
NCT02733159 · Phase 2 · registry result, not featured evidence
Overall Survival 20.7 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 8 more results
23 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03634241 · Phase 2 · registry result, not featured evidence
22.3 months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
13.3 months
NCT02955758 · Phase 2 · registry result, not featured evidence
35.6 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
56.7 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
9.8 months
NCT02733159 · Phase 2 · registry result, not featured evidence

+ 47 further endpoints in the CSV export.

Cervical Cancer

Shared mechanism: PD-1 · full Cervical Cancer pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Cervical Cancermonoclonal antibody
Reliable signal

NCT04221945 · Phase 3 · completed

Patients were randomly assigned to pembrolizumab or a matching placebo with chemoradiotherapy, with patients, investigators and assessors blinded, and 1,060 were enrolled against a planned 980 from the protocol's sample-size calculation. Both primary endpoints were met: progression-free survival (hazard ratio 0.72) and overall survival (hazard ratio 0.73) were significantly better with pembrolizumab.

Next expected readout: December 2026 · NCT05082259 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Cervical Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Cervical Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pembrolizumab: registry results are on file for Cervical Cancer, but their comparison mappings are not yet available.

Pembrolizumab berahyaluronidase alfa: no structured comparison results are available for Cervical Cancer.

Gastric Cancer

Shared mechanism: PD-1 · full Gastric Cancer pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Gastric Cancermonoclonal antibody
Reliable signal

NCT03615326 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial; 698 participants were randomized in its main cohort, more than the approximately 692 its published sample-size calculation required. Both primary endpoints were met: progression-free survival by blinded central review (hazard ratio 0.73) and overall survival (hazard ratio 0.80) were significantly better with pembrolizumab.

Next expected readout: December 2026 · NCT05041153 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Gastric Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Gastric Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pembrolizumab berahyaluronidase alfa: no structured comparison results are available for Gastric Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

Disease Control 47.6% (n=21)2.2 µg/kg
responder rate · % of participants
No placebo or comparator arm
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
71.4% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
47.6% (n=21)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
78.6% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
51.6% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
77.4% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
53.5% (n=99)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4% (n=105)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
56.7% (n=30)
NCT03797326 · Phase 2 · registry result, not featured evidence
57.4% (n=101)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
64.7% (n=102)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
37.9% (n=103)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 12.4 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 14 more results
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
8.5 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
2.8 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
8.5 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
2.8 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
22.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
15.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03797326 · Phase 2 · registry result, not featured evidence
4.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
5.8 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
PFS 2.1 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 15 more results
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
1.4 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
1.4 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.5 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence
3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
2.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 4.4 months2.2 µg/kg
time to event · months
No placebo or comparator arm
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
show 9 more results
12.9 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
11.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
21.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence
8.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
ORR 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 5 more results
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
9.5% (n=21)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
28.6% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Complete 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
1.7% (n=118)100 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=13)75 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=10)50 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Partial 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
9.3% (n=118)100 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Available safety results

Pembrolizumab

Dropout rate
n/a: no completion milestoneCohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
n/a: no completion milestoneCohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
25%Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
0%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
4.8%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
0%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
—Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
—Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
50%2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
66.7%1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
0%1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
51.6%Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
61.3%Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
57.6%Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4%Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
40%Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
29.7%Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
60.8%Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
47.6%Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
66.7%Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
60%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
35%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
hypertension 51.6%
diarrhoea 45.2%
hypothyroidism 45.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 19 more results
hypertension 67.7%
diarrhoea 61.3%
decreased appetite 48.4%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 37.4%
nausea 31.3%
asthenia 30.3%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.2%
diarrhoea 44.8%
decreased appetite 43.8%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.7%
diarrhoea 53.3%
dysphonia 40%
NCT03797326 · Phase 2 · registry result, not featured evidence
hypertension 50.5%
asthenia 28.7%
hypothyroidism 27.7%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.9%
diarrhoea 41.2%
fatigue 39.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 53.4%
nausea 35.9%
decreased appetite 32%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 50%
alanine aminotransferase increased 33.3%
diarrhea 33.3%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 80%
dizziness 80%
fatigue 80%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
dizziness 45%
decreased appetite 30%
dyspnea 30%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
abdominal pain 66.7%
blood alkaline phosphatase increased 66.7%
fatigue 66.7%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Melanoma

Shared mechanism: PD-1 · full Melanoma pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Melanomamonoclonal antibody
Partial signal

NCT01866319 · Phase 3 · completed

The trial randomized 834 participants to two pembrolizumab schedules or active-control ipilimumab, with progression assessed by blinded independent radiology review and statistically significant improvements in progression-free survival and overall survival for both pembrolizumab schedules versus ipilimumab. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the objective clinical endpoints and favorable results.

Next expected readout: December 2026 · NCT02644369 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Melanomamonoclonal antibody
Partial signal

NCT06099782 · Phase 2 · active, not recruiting

Patients were randomized to the order in which they received the two routes, but the study was open-label, and its primary endpoint was the share of patients who preferred the subcutaneous route, a single percentage with no formal comparison. It measured preference and convenience, not whether the drug controls cancer, so it is limited evidence.

No aligned efficacy figure on record for this race.

Results for Melanoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pembrolizumab berahyaluronidase alfa: registry results are on file for Melanoma, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

Brain Metastasis 54.1% (n=37)
responder rate · % of participants
No placebo or comparator arm
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
NCT02681549 · Phase 2 · registry result, not featured evidence
Intracranial ORR 54.1% (n=37)
responder rate · % of participants
No placebo or comparator arm
Intracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
Intracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
Extracranial 56.3% (n=37)
responder rate · % of participants
No placebo or comparator arm
Extracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
Extracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
PFS 14.4 months
time to event · months
No placebo or comparator arm
Median overall PFS
NCT02681549 · Phase 2 · registry result, not featured evidence · converted to months from 1.2 years as posted
show 1 more result
NA months
Median overall PFS
NCT02681549 · Phase 2 · registry result, not featured evidence
ORR 7% (n=14)280 mg PO BID
responder rate · % of participants
No placebo or comparator arm
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 16 more results
29.4% (n=313)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
36.7% (n=180)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
21.6% (n=287)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
19.3% (n=202)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
39.9% (n=313)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
45.6% (n=180)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
28.9% (n=287)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
22.3% (n=202)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
22.2% (n=18)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.2% (n=76)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
18.9% (n=53)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5.4% (n=37)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
30.2% (n=162)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
19.7% (n=61)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
35.2% (n=162)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
23% (n=61)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
Clinical Benefit 33.3% (n=18) @ 24wk5 mg weekly
responder rate · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
35.8% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
8.1% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
22.2% (n=18) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
30.2% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.7% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
PFS 6mo 16.7% (n=18) @ 24wk5 mg weekly
event count · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
show 7 more results
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
37.7% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
8.1% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
16.7% (n=18) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
32.1% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
5.4% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
PFS 3.7 months10 mg/kg Q3W
time to event · months
No placebo or comparator arm
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
show 19 more results
5.6 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
6.6 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
9.6 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
3.7 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
3.4 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
4.4 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
5.6 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.4 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.69 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.96 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.9 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
8.2 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
3.3 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
4.3 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
Overall Survival 22.5 months10 mg/kg Q3W
time to event · months
No placebo or comparator arm
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
show 12 more results
26.8 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
13.1 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
13.4 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
25.2 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
11.73 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
12.52 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.79 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
23.1 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
8.9 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
32.8 months27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
12.2 months18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
Duration of Response NA months10 mg/kg Q3W
time to event · months
No placebo or comparator arm
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
show 18 more results
NA months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
20.7 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
15.61 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
7.33 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
NA months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.14 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
Time to Response 4.3 months5 mg weekly
time to event · months
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 6 more results
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.95 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.17 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.29 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.95 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
Complete 0% (n=10) @ 52wk
responder rate · % of participants
No placebo or comparator arm
Complete response (CR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
0% (n=5) @ 52wk*
Complete response (CR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted

+ 7 further endpoints in the CSV export.

Available safety results

Pembrolizumab

Dropout rate
89.3%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
0%30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
0%27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
0%18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
57.1%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
92.3%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
92.5%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
91.6%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
93.2%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
100%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
100%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
89%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
90.2%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
100%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
100%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
100%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
—30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
12%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
15.3%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10.3%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
16.9%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
16.7%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
66.7%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
9.1%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
11.5%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
33.3%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Serious AEs
20.7%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
22.2%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
57.1%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
55.6%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
43.4%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45.3%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
36.8%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
20%Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
33.3%30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
41.7%27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
14.3%18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
14.3%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
43.9%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
41.2%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
42.6%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
41.5%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
30%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
33.3%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
42.6%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
55.7%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
0%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
33.3%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
200 mg IV Q3W
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
show 56 more results
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
5 mg weekly
fatigue 66.7%
decreased appetite 55.6%
cough 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 85.7%
cough 42.9%
hypophosphataemia 42.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 77.8%
musculoskeletal and connective tissue disorders 55.6%
cough 38.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 47.4%
musculoskeletal and connective tissue disorders 44.7%
decreased appetite 35.5%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
nausea 56.6%
fatigue 54.7%
musculoskeletal and connective tissue disorders 45.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 57.9%
musculoskeletal and connective tissue disorders 44.7%
blood alkaline phosphatase increased 36.8%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
3 mg weekly
decreased appetite 50%
cough 33.3%
diarrhoea 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
dyspnea 90%
fatigue 90%
pain 70%
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 100%
cough 80%
pain 60%
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
30 Gy over 5 fractions
headache 33.3%
agitation 16.7%
dermatitis, other 16.7%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
27 Gy over 3 fractions
symptomatic radionecrosis 16.7%
constipation 8.3%
dermatitis, other 8.3%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
18-21 Gy in one fraction
symptomatic radionecrosis 14.3%
agitation 0%
constipation 0%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
20 mg/kg
hypertension 28.6%
anemia 14.3%
arthralgia 14.3%
NCT03236935 · Phase 1 · registry result, not featured evidence
10 mg/kg Q2W
fatigue 58.9%
diarrhoea 38.9%
nausea 38.3%
NCT01295827 · Phase 1 · registry result, not featured evidence
10 mg/kg Q3W
fatigue 52.1%
diarrhoea 35.5%
nausea 34.5%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10 mg/kg Q2W
fatigue 38.6%
decreased appetite 27.2%
dyspnoea 25.7%
NCT01295827 · Phase 1 · registry result, not featured evidence
10 mg/kg Q3W
fatigue 42.5%
decreased appetite 30.7%
cough 30%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10 mg/kg Q2W
fatigue 50%
decreased appetite 30%
constipation 20%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
3 mg/kg Q2W
back pain 66.7%
nausea 66.7%
breast pain 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence
2 mg/kg Q3W
fatigue 47.5%
nausea 34.6%
diarrhoea 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
2 mg/kg Q3W
fatigue 27.9%
diarrhoea 19.7%
constipation 16.4%
NCT01295827 · Phase 1 · registry result, not featured evidence
1 mg/kg Q2W
pruritus 75%
abdominal pain upper 25%
anaemia 25%
NCT01295827 · Phase 1 · registry result, not featured evidence
bradycardia 25%
diarrhoea 25%
fatigue 25%
NCT01295827 · Phase 1 · registry result, not featured evidence
diarrhoea 66.7%
fatigue 66.7%
pruritus 66.7%
NCT01295827 · Phase 1 · registry result, not featured evidence
decreased appetite 66.7%
fatigue 50%
depression 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence

Colorectal Cancer

Shared mechanism: PD-1 · full Colorectal Cancer pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Colorectal Cancermonoclonal antibody
Weak signal

NCT02460198 · Phase 2 · completed

The study treated 124 participants with pembrolizumab in a non-randomized, open-label, single-group design without a placebo or active comparator. Although the primary endpoint was an objective tumor response measure assessed by central imaging, the study had no formal between-group comparison and therefore provides limited evidence of pembrolizumab’s comparative benefit.

Next expected readout: December 2026 · NCT05784688 (registry estimate)

Reported efficacy

Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) (not_applicable)

Result source: NCT02460198

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Colorectal Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2030 · NCT07750158 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Colorectal Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pembrolizumab berahyaluronidase alfa: no structured comparison results are available for Colorectal Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

Disease Control 51.6% (n=31)
responder rate · % of participants
No placebo or comparator arm
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
77.4% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
53.5% (n=99)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4% (n=105)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
56.7% (n=30)
NCT03797326 · Phase 2 · registry result, not featured evidence
57.4% (n=101)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
64.7% (n=102)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
37.9% (n=103)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 12.4 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 17 more results
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
15.61 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
7.33 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
NA months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.14 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
22.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
15.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03797326 · Phase 2 · registry result, not featured evidence
4.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
5.8 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
PFS 2.1 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 19 more results
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.4 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.69 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.96 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.5 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence
3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
2.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Overall Survival NA months1200 ug/kg
time to event · months
No placebo or comparator arm
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 22 more results
9.4 months960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
NA months480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
25.2 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
11.73 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
12.52 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.79 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
11.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
21.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence
8.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
9.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
17.3 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
5.9 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
9.3 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
16 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
11.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
6.7 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
ORR 0% (n=14)
responder rate · % of participants
No placebo or comparator arm
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
0% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
13.3% (n=15)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.7% (n=27)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.8% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.8% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=12)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
Immune ORR 0% (n=14)
responder rate · % of participants
No placebo or comparator arm
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
3.8% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
13.3% (n=15)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
11.1% (n=27)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
7.7% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.8% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=12)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response NA months480 ug/kg
time to event · months
No placebo or comparator arm
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
NA months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
13.1 months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
NA months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
8.6 months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
NA months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 66.7% (n=6)1200 ug/kg
responder rate · % of participants
No placebo or comparator arm
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 10 more results
0% (n=3)960 ug/kg
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7% (n=3)480 ug/kg
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
21.4% (n=14)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
42.3% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
20% (n=15)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
40.7% (n=27)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
30.8% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
30.8% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
19.2% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
25% (n=12)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
PFS 5.3 months1200 ug/kg
time to event · months
No placebo or comparator arm
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 10 more results
1.3 months960 ug/kg
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
8.6 months480 ug/kg
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.2 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.3 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.7 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.3 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
ORR 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
22.2% (n=18)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.2% (n=76)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
18.9% (n=53)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5.4% (n=37)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
Clinical Benefit 33.3% (n=18) @ 24wk5 mg weekly
responder rate · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
35.8% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
8.1% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
22.2% (n=18) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
30.2% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.7% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
PFS 6mo 16.7% (n=18) @ 24wk5 mg weekly
event count · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
show 7 more results
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
37.7% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
8.1% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
16.7% (n=18) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
32.1% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
5.4% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted

+ 6 further endpoints in the CSV export.

Available safety results

Pembrolizumab

Dropout rate
n/a: no completion milestoneCohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 44 more results
n/a: no completion milestoneCohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone30 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
100%1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
100%960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7%480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
57.1%1400 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
87.5%1100 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
73.8%Part 2, Group 1: CRC MMR-proficien
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
93.5%Part 2, Group 2: Pancreatic Cancer
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
75%Part 2, Group 3: NSCLC PD-L1 Low,
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
73.7%Part 2, Group 4a: Refractory / Rel
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Part 2, Group 4b: Refractory/Relap
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 44 more results
—Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
—Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—100 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
—30 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
—1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—1400 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—1100 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 1: CRC MMR-proficien
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 2: Pancreatic Cancer
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 3: NSCLC PD-L1 Low,
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4a: Refractory / Rel
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4b: Refractory/Relap
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
51.6%Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 44 more results
61.3%Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
57.6%Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4%Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
40%Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
29.7%Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
60.8%Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
47.6%Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
27.8%100 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
33.3%30 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
16.7%1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
33.3%960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7%480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
25%Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
82.4%Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
64.7%Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
51.7%Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
71.4%Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
56.3%Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
79.4%Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
69.2%Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
22.2%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
57.1%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
55.6%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
43.4%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45.3%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
36.8%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—1400 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—1100 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 1: CRC MMR-proficien
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 2: Pancreatic Cancer
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 3: NSCLC PD-L1 Low,
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4a: Refractory / Rel
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4b: Refractory/Relap
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
hypertension 51.6%
diarrhoea 45.2%
hypothyroidism 45.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 35 more results
hypertension 67.7%
diarrhoea 61.3%
decreased appetite 48.4%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 37.4%
nausea 31.3%
asthenia 30.3%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.2%
diarrhoea 44.8%
decreased appetite 43.8%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.7%
diarrhoea 53.3%
dysphonia 40%
NCT03797326 · Phase 2 · registry result, not featured evidence
hypertension 50.5%
asthenia 28.7%
hypothyroidism 27.7%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.9%
diarrhoea 41.2%
fatigue 39.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 53.4%
nausea 35.9%
decreased appetite 32%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
100 mg + 200 mg
nausea 29.6%
fatigue 25.9%
pyrexia 22.2%
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
30 mg + 200 mg
fatigue 33.3%
decreased appetite 27.5%
pyrexia 23.5%
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
1200 ug/kg
chills 83.3%
fatigue 66.7%
injection site erythema 66.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
960 ug/kg
oedema peripheral 66.7%
anaemia 33.3%
blood bilirubin increased 33.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
480 ug/kg
headache 100%
pyrexia 100%
chills 66.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
alanine aminotransferase increased 31.3%
cough 31.3%
oedema peripheral 31.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 41.2%
nausea 29.4%
oedema peripheral 23.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 47.1%
decreased appetite 35.3%
pruritus 23.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
nausea 48.3%
fatigue 44.8%
pyrexia 41.4%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 42.9%
pyrexia 42.9%
decreased appetite 35.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
pyrexia 43.8%
fatigue 37.5%
nausea 31.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 47.1%
anaemia 32.4%
decreased appetite 26.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
aspartate aminotransferase increased 38.5%
anaemia 30.8%
fatigue 30.8%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 66.7%
decreased appetite 55.6%
cough 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 85.7%
cough 42.9%
hypophosphataemia 42.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 77.8%
musculoskeletal and connective tissue disorders 55.6%
cough 38.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 47.4%
musculoskeletal and connective tissue disorders 44.7%
decreased appetite 35.5%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
nausea 56.6%
fatigue 54.7%
musculoskeletal and connective tissue disorders 45.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 57.9%
musculoskeletal and connective tissue disorders 44.7%
blood alkaline phosphatase increased 36.8%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
3 mg weekly
decreased appetite 50%
cough 33.3%
diarrhoea 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Renal Cell Carcinoma

Shared mechanism: PD-1 · full Renal Cell Carcinoma pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Renal Cell Carcinomamonoclonal antibody
Partial signal

NCT02853331 · Phase 3 · completed

The trial randomly assigned 861 participants to open-label pembrolizumab plus axitinib or active-controlled sunitinib monotherapy, with progression assessed by blinded independent central imaging review. Both prespecified primary endpoints favored the combination: progression-free survival was significantly improved (HR 0.69, p=0.00012) and overall survival was significantly improved (HR 0.53, p=0.00005), but the open-label design limits the evidence strength.

Next expected readout: December 2026 · NCT05319015 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11) (met)

Result source: NCT02811861

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Renal Cell Carcinomamonoclonal antibody
Partial signal

NCT06099782 · Phase 2 · active, not recruiting

Patients were randomized to the order in which they received the two routes, but the study was open-label, and its primary endpoint was the share of patients who preferred the subcutaneous route, a single percentage with no formal comparison. It measured preference and convenience, not whether the drug controls cancer, so it is limited evidence.

No aligned efficacy figure on record for this race.

Results for Renal Cell Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pembrolizumab berahyaluronidase alfa: registry results are on file for Renal Cell Carcinoma, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

ORR 20% (n=5)3.2/4 mg
event count · % of participants
No placebo or comparator arm
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 19 more results
20% (n=5)*3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.3% (n=95)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 6 Participants as posted
10.7% (n=28)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
39.6% (n=48)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
46.7% (n=15)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
0% (n=6)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
16.7% (n=6)*0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
35.7% (n=14)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
100% (n=1)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=6)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
33.3% (n=3)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=5)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
25% (n=4)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
ORR 7% (n=14)280 mg PO BID
responder rate · % of participants
No placebo or comparator arm
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 4 more results
0% (n=10)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Complete 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
1.7% (n=118)100 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=13)75 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=10)50 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Partial 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
9.3% (n=118)100 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 12.4 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 2 more results
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
PFS 2.1 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Available safety results

Pembrolizumab

Dropout rate
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 35 more results
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 35 more results
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 35 more results
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 31 more results
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Breast Cancer

Shared mechanism: PD-1 · full Breast Cancer pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Breast Cancermonoclonal antibody
Partial signal

NCT03036488 · Phase 3 · completed

Patients were randomly assigned to pembrolizumab or a matching placebo with chemotherapy, with patients, doctors and assessors all blinded, and both primary endpoints were met: pathological complete response (P<0.001) and event-free survival (hazard ratio 0.63, P<0.001). No power calculation was reported in the sources available for this trial, so it cannot be confirmed that the trial enrolled the number of patients it planned.

Next expected readout: November 2026 · NCT06545331 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Breast Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pembrolizumab berahyaluronidase alfa: no structured comparison results are available for Breast Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

PFS 7.5 vs 5.6 placebo months
time to event · months
NCT02819518 · Phase 3 · combination
show 7 more results
7.6 vs 5.6 placebo months
NCT02819518 · Phase 3 · combination
9.7 vs 5.6 placebo months
NCT02819518 · Phase 3 · combination
2.1 vs 3.4 Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
2.1 vs 3.1 Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
2.1 vs 3.3 Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
2.06 vs 2.63 Carboplatin months @ 18wk
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
4.1 vs 4.2 Eribulin Mesylate months
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 17.2 vs 15.5 placebo months
time to event · months
NCT02819518 · Phase 3 · combination
show 6 more results
17.6 vs 16 placebo months
NCT02819518 · Phase 3 · combination
23 vs 16.1 placebo months
NCT02819518 · Phase 3 · combination
12.7 vs 11.6 Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
10.7 vs 10.2 Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
9.9 vs 10.8 Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
13.4 vs 12.5 Eribulin Mesylate months
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
ORR 40.8% (n=566) vs 37% (n=281) placebo
responder rate · % of participants
NCT02819518 · Phase 3 · combination
show 7 more results
44.9% (n=425) vs 38.9% (n=211) placebo
NCT02819518 · Phase 3 · combination
52.7% (n=220) vs 40.8% (n=103) placebo
NCT02819518 · Phase 3 · combination
17.7% (n=96) vs 9.2% (n=98) Chemotherapy
NCT02555657 · Phase 3 · registry result, not featured evidence
12.3% (n=203) vs 9.4% (n=202) Chemotherapy
NCT02555657 · Phase 3 · registry result, not featured evidence
9.6% (n=312) vs 10.6% (n=310) Chemotherapy
NCT02555657 · Phase 3 · registry result, not featured evidence
8% (n=51) vs 12.5% (n=24) Carboplatin @ 18wk
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
27% (n=44) vs 34% (n=44) Eribulin Mesylate
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
Duration of Response NA vs 6.5 placebo months
time to event · months
NCT02819518 · Phase 3 · combination
show 6 more results
NA vs 6.8 placebo months
NCT02819518 · Phase 3 · combination
NA vs 7.3 placebo months
NCT02819518 · Phase 3 · combination
NA vs 7.1 Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
12.2 vs NA Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
12.2 vs NA Chemotherapy months
NCT02555657 · Phase 3 · registry result, not featured evidence
0.6 vs 2.1 Eribulin Mesylate months
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
Disease Control 56% (n=566) vs 51.2% (n=281) placebo
responder rate · % of participants
NCT02819518 · Phase 3 · combination
show 7 more results
58.6% (n=425) vs 53.6% (n=211) placebo
NCT02819518 · Phase 3 · combination
65% (n=220) vs 54.4% (n=103) placebo
NCT02819518 · Phase 3 · combination
19.8% (n=96) vs 17.3% (n=98) Chemotherapy
NCT02555657 · Phase 3 · registry result, not featured evidence
14.3% (n=203) vs 15.8% (n=202) Chemotherapy
NCT02555657 · Phase 3 · registry result, not featured evidence
12.2% (n=312) vs 18.7% (n=310) Chemotherapy
NCT02555657 · Phase 3 · registry result, not featured evidence
20% (n=51) vs 17% (n=24) Carboplatin Monotherapy, then Pembrolizumab for participants who progress only @ 18wk
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
18% (n=51) vs 17% (n=24) Carboplatin @ 18wk
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS -3.52 vs -2.15 placebo score @ 15wk
absolute change · score
NCT02819518 · Phase 3 · combination
show 2 more results
-3.92 vs -3.15 placebo score @ 15wk
NCT02819518 · Phase 3 · combination
-2.69 vs -0.88 placebo score @ 15wk
NCT02819518 · Phase 3 · combination
EORTC QLQ-BR23 Systemic Therapy Side Effects 12.5 vs 12.36 placebo score @ 15wk
absolute change · score
NCT02819518 · Phase 3 · combination
show 2 more results
13 vs 11.86 placebo score @ 15wk
NCT02819518 · Phase 3 · combination
13.56 vs 13.26 placebo score @ 15wk
NCT02819518 · Phase 3 · combination
Disease Control 58.5% (n=53) @ 40wk
responder rate · % of participants
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 18 more results
41.8% (n=55) @ 40wk
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
81% (n=59)2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
59% (n=32)2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
69% (n=36)1.5 mg/kg (2Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
77% (n=53)1.25 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=2)1.0 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
51.6% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
77.4% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
53.5% (n=99)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4% (n=105)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
56.7% (n=30)
NCT03797326 · Phase 2 · registry result, not featured evidence
57.4% (n=101)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
64.7% (n=102)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
37.9% (n=103)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.6% (n=170)
NCT02447003 · Phase 2 · registry result, not featured evidence
23.8% (n=84)
NCT02447003 · Phase 2 · registry result, not featured evidence
9.5% (n=105)
NCT02447003 · Phase 2 · registry result, not featured evidence
60% (n=20) @ 18wk
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 14.4 months
time to event · months
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 29 more results
21.5 months
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
5.8 months2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
4.5 months2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
8.3 months1.5 mg/kg (2Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
4.4 months1.25 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
4.2 months1.0 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
22.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
15.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03797326 · Phase 2 · registry result, not featured evidence
4.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
5.8 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
20.4 months
NCT02768701 · Phase 2 · registry result, not featured evidence · combination
4.5 months @ 13wk
NCT02730130 · Phase 2 · registry result, not featured evidence · combination
7.3 months
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
4 months
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02447003 · Phase 2 · registry result, not featured evidence
10.4 months
NCT02447003 · Phase 2 · registry result, not featured evidence
NA months
NCT02447003 · Phase 2 · registry result, not featured evidence
9 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
8.6 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
8.3 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
8.3 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
8.2 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
8.2 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
3.5 months
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
PFS 3.4 months
time to event · months
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 31 more results
2.5 months
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
4.2 months2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
3.5 months2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
4.2 months1.5 mg/kg (2Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
4.8 months1.25 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
3.3 months1.0 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
4.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.5 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence
3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
2.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
5.2 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
1.8 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
1.8 months
NCT02768701 · Phase 2 · registry result, not featured evidence · combination
4.1 months
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
3.9 months
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
2 months
NCT02447003 · Phase 2 · registry result, not featured evidence
2.1 months
NCT02447003 · Phase 2 · registry result, not featured evidence
2 months
NCT02447003 · Phase 2 · registry result, not featured evidence
4.2 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
4.1 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
4.1 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
6.1 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
4.1 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
4.2 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
2.7 months
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
2.5 months
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
9.6 months
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
Overall Survival NA months1200 ug/kg
time to event · months
No placebo or comparator arm
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 40 more results
9.4 months960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
NA months480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
17.1 months
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
9.4 months
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
14.8 months2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
14.6 months2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
NA months1.5 mg/kg (2Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
19.4 months1.25 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
NA months1.0 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
11.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
21.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence
8.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
15.6 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
17.2 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
6.3 months
NCT02768701 · Phase 2 · registry result, not featured evidence · combination
27.6 months
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
9 months
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
9 months
NCT02447003 · Phase 2 · registry result, not featured evidence
18 months
NCT02447003 · Phase 2 · registry result, not featured evidence
8.8 months
NCT02447003 · Phase 2 · registry result, not featured evidence
9.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
17.3 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
5.9 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
9.3 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
16 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
11.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
6.7 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
17.4 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
15.5 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
16.1 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
21 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
14 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
16.3 months
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
NA months
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
ORR 20% (n=5)3.2/4 mg
event count · % of participants
No placebo or comparator arm
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 25 more results
20% (n=5)*3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.3% (n=95)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 6 Participants as posted
10.7% (n=28)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
39.6% (n=48)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
46.7% (n=15)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
0% (n=6)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
16.7% (n=6)*0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
35.7% (n=14)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
100% (n=1)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=6)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
33.3% (n=3)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=5)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
25% (n=4)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
50% (n=10)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
10% (n=20)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
19% (n=21)*
NCT03018080 · Phase 2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
42.1% (n=19)*
NCT03018080 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted
0.15% (n=40)
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=12)
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination

+ 16 further endpoints in the CSV export.

Available safety results

Pembrolizumab

Dropout rate
n/a: no completion milestonePart 1: Pembrolizumab + Gemcitabin
NCT02819518 · Phase 3 · combination
show 88 more results
n/a: no completion milestonePart 1: Pembrolizumab + Nab-Paclit
NCT02819518 · Phase 3 · combination
n/a: no completion milestonePart 1: Pembrolizumab + Paclitaxel
NCT02819518 · Phase 3 · combination
n/a: no completion milestonePart 2: Pembrolizumab + Chemothera
NCT02819518 · Phase 3 · combination
n/a: no completion milestonePembrolizumab
NCT02555657 · Phase 3 · registry result, not featured evidence
—Pembrolizumab First Course
NCT02555657 · Phase 3 · registry result, not featured evidence
—Pembrolizumab Second Course
NCT02555657 · Phase 3 · registry result, not featured evidence
1.9%
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
4.3%
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
20%
NCT02768701 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02730130 · Phase 2 · registry result, not featured evidence · combination
57.1%Arm A (Phased Pembrolizumab Regime
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
100%Arm B (Concurrent Pembrolizumab Re
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort A: Pembrolizumab
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort A: Pembrolizumab First Cour
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort A: Pembrolizumab Second Cou
NCT02447003 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort B: Pembrolizumab
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort B: Pembrolizumab First Cour
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort B: Pembrolizumab Second Cou
NCT02447003 · Phase 2 · registry result, not featured evidence
100%1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
100%960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7%480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1.5 mg/kg (2Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1.25 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1.0 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePhase 1: Niraparib 300 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePhase 1: Niraparib 200 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200 mg + Pem
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200mg + Pemb
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200 mg + P
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200mg + Pe
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Overall: Eribulin Mesylate + Pembr
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestoneStratum 1: Eribulin Mesylate + Pem
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestoneStratum 2: Eribulin Mesylate + Pem
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
0%2 mg/kg
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II (PD-L1+ and PD-L1-)
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
7.5%Phase II PD-L1+
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase II PD-L1-
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—Part 1: Pembrolizumab + Gemcitabin
NCT02819518 · Phase 3 · combination
show 88 more results
—Part 1: Pembrolizumab + Nab-Paclit
NCT02819518 · Phase 3 · combination
—Part 1: Pembrolizumab + Paclitaxel
NCT02819518 · Phase 3 · combination
—Part 2: Pembrolizumab + Chemothera
NCT02819518 · Phase 3 · combination
—Pembrolizumab
NCT02555657 · Phase 3 · registry result, not featured evidence
—Pembrolizumab First Course
NCT02555657 · Phase 3 · registry result, not featured evidence
—Pembrolizumab Second Course
NCT02555657 · Phase 3 · registry result, not featured evidence
—
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
—Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
—
NCT02768701 · Phase 2 · registry result, not featured evidence · combination
—
NCT02730130 · Phase 2 · registry result, not featured evidence · combination
—Arm A (Phased Pembrolizumab Regime
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Concurrent Pembrolizumab Re
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pembrolizumab
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort A: Pembrolizumab First Cour
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort A: Pembrolizumab Second Cou
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort B: Pembrolizumab
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort B: Pembrolizumab First Cour
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort B: Pembrolizumab Second Cou
NCT02447003 · Phase 2 · registry result, not featured evidence
—1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
—2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
—2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
—1.5 mg/kg (2Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
—1.25 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
—1.0 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Niraparib 300 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Niraparib 200 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200 mg + Pem
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200mg + Pemb
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200 mg + P
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200mg + Pe
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Overall: Eribulin Mesylate + Pembr
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
12.1%Stratum 1: Eribulin Mesylate + Pem
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
10.9%Stratum 2: Eribulin Mesylate + Pem
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—2 mg/kg
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II (PD-L1+ and PD-L1-)
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II PD-L1+
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II PD-L1-
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
Serious AEs
81.8%Part 1: Pembrolizumab + Gemcitabin
NCT02819518 · Phase 3 · combination
show 88 more results
23.1%Part 1: Pembrolizumab + Nab-Paclit
NCT02819518 · Phase 3 · combination
40%Part 1: Pembrolizumab + Paclitaxel
NCT02819518 · Phase 3 · combination
—Part 2: Pembrolizumab + Chemothera
NCT02819518 · Phase 3 · combination
—Pembrolizumab
NCT02555657 · Phase 3 · registry result, not featured evidence
21%Pembrolizumab First Course
NCT02555657 · Phase 3 · registry result, not featured evidence
12.5%Pembrolizumab Second Course
NCT02555657 · Phase 3 · registry result, not featured evidence
28.8%
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
51.6%Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
61.3%Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
57.6%Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4%Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
40%Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
29.7%Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
60.8%Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
47.6%Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
30%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
10%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
61.4%
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
45%
NCT02768701 · Phase 2 · registry result, not featured evidence · combination
100%
NCT02730130 · Phase 2 · registry result, not featured evidence · combination
19%Arm A (Phased Pembrolizumab Regime
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
36.8%Arm B (Concurrent Pembrolizumab Re
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pembrolizumab
NCT02447003 · Phase 2 · registry result, not featured evidence
27.1%Cohort A: Pembrolizumab First Cour
NCT02447003 · Phase 2 · registry result, not featured evidence
0%Cohort A: Pembrolizumab Second Cou
NCT02447003 · Phase 2 · registry result, not featured evidence
—Cohort B: Pembrolizumab
NCT02447003 · Phase 2 · registry result, not featured evidence
22.6%Cohort B: Pembrolizumab First Cour
NCT02447003 · Phase 2 · registry result, not featured evidence
50%Cohort B: Pembrolizumab Second Cou
NCT02447003 · Phase 2 · registry result, not featured evidence
16.7%1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
33.3%960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7%480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
25%Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
82.4%Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
64.7%Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
51.7%Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
71.4%Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
56.3%Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
79.4%Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
69.2%Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7%2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
57.4%2.5 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
57.1%2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
50%2.0 mg/kg (Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
37.8%1.5 mg/kg (2Q3WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
52.8%1.25 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
33.3%1.0 mg/kg (Q1WK)
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
57.1%Phase 1: Niraparib 300 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
85.7%Phase 1: Niraparib 200 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
41.5%Phase 2 OC: Niraparib 200 mg + Pem
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200mg + Pemb
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
43.6%Phase 2 TNBC: Niraparib 200 mg + P
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200mg + Pe
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
52.1%Overall: Eribulin Mesylate + Pembr
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
45.5%Stratum 1: Eribulin Mesylate + Pem
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
56.4%Stratum 2: Eribulin Mesylate + Pem
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—2 mg/kg
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
48.1%Phase II (PD-L1+ and PD-L1-)
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II PD-L1+
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II PD-L1-
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
10%
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
anaemia 72.7% (placebo 49.8%)
neutropenia 63.6% (placebo 38.8%)
constipation 54.5% (placebo 27.4%)
NCT02819518 · Phase 3 · combination
show 76 more results
decreased appetite 61.5% (placebo 13.9%)
asthenia 46.2% (placebo 16.7%)
nausea 46.2% (placebo 46.3%)
NCT02819518 · Phase 3 · combination
alopecia 50% (placebo 34.5%)
anaemia 50% (placebo 49.8%)
headache 50% (placebo 23.5%)
NCT02819518 · Phase 3 · combination
fatigue 17.8%
cough 17.2%
constipation 16.2%
NCT02555657 · Phase 3 · registry result, not featured evidence
alanine aminotransferase increased 12.5%
arthralgia 12.5%
aspartate aminotransferase increased 12.5%
NCT02555657 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 34.6%
platelet count decreased 30.8%
anemia 26.9%
NCT03095352 · Phase 2 · registry result, not featured evidence · combination
hypertension 51.6%
diarrhoea 45.2%
hypothyroidism 45.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 67.7%
diarrhoea 61.3%
decreased appetite 48.4%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 37.4%
nausea 31.3%
asthenia 30.3%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.2%
diarrhoea 44.8%
decreased appetite 43.8%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.7%
diarrhoea 53.3%
dysphonia 40%
NCT03797326 · Phase 2 · registry result, not featured evidence
hypertension 50.5%
asthenia 28.7%
hypothyroidism 27.7%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.9%
diarrhoea 41.2%
fatigue 39.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 53.4%
nausea 35.9%
decreased appetite 32%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
fatigue 90%
nausea 90%
white blood cell decreased 90%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
fatigue 75%
alkaline phosphatase increased 50%
aspartate aminotransferase increased 45%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
fatigue 88.6%
nausea 56.8%
alopecia 54.5%
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
fatigue 75%
anemia 70%
lymphocyte count decreased 62.5%
NCT02768701 · Phase 2 · registry result, not featured evidence · combination
fatigue 11.8%
lymphopenia 11.8%
nausea 11.8%
NCT02730130 · Phase 2 · registry result, not featured evidence · combination
fatigue 71.4%
peripheral sensory neuropathy 42.9%
alopecia 38.1%
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
peripheral sensory neuropathy 68.4%
fatigue 57.9%
alopecia 42.1%
NCT03018080 · Phase 2 · registry result, not featured evidence · combination
fatigue 28.8%
cough 22.9%
nausea 20%
NCT02447003 · Phase 2 · registry result, not featured evidence
pain in extremity 100%
weight increased 100%
abdominal pain 0%
NCT02447003 · Phase 2 · registry result, not featured evidence
fatigue 35.7%
nausea 27.4%
cough 23.8%
NCT02447003 · Phase 2 · registry result, not featured evidence
cough 50%
abdominal pain 25%
alanine aminotransferase increased 25%
NCT02447003 · Phase 2 · registry result, not featured evidence
1200 ug/kg
chills 83.3%
fatigue 66.7%
injection site erythema 66.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
960 ug/kg
oedema peripheral 66.7%
anaemia 33.3%
blood bilirubin increased 33.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
480 ug/kg
headache 100%
pyrexia 100%
chills 66.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
alanine aminotransferase increased 31.3%
cough 31.3%
oedema peripheral 31.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 41.2%
nausea 29.4%
oedema peripheral 23.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 47.1%
decreased appetite 35.3%
pruritus 23.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
nausea 48.3%
fatigue 44.8%
pyrexia 41.4%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 42.9%
pyrexia 42.9%
decreased appetite 35.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
pyrexia 43.8%
fatigue 37.5%
nausea 31.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 47.1%
anaemia 32.4%
decreased appetite 26.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
aspartate aminotransferase increased 38.5%
anaemia 30.8%
fatigue 30.8%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg (Q3WK)
fatigue 83.3%
diarrhoea 75%
nausea 75%
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg (Q3WK)
nausea 68.1%
fatigue 66%
diarrhoea 55.3%
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
2.0 mg/kg (Q3WK)
nausea 100%
alopecia 71.4%
fatigue 71.4%
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
2.0 mg/kg (Q3WK)
nausea 46.2%
fatigue 42.3%
constipation 38.5%
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
1.5 mg/kg (2Q3WK)
nausea 54.1%
diarrhoea 43.2%
fatigue 43.2%
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
1.25 mg/kg (Q1WK)
nausea 66%
fatigue 60.4%
diarrhoea 56.6%
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
1.0 mg/kg (Q1WK)
sinus tachycardia 66.7%
alopecia 33.3%
altered state of consciousness 33.3%
NCT03310957 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 71.4%
dyspnoea 57.1%
nausea 57.1%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 71.4%
constipation 71.4%
fatigue 57.1%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 60.4%
nausea 60.4%
constipation 52.8%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
nausea 61.8%
fatigue 54.5%
anaemia 43.6%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 66.5%
nausea 57.5%
peripheral sensory neuropathy 41.3%
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 72.7%
nausea 68.2%
alopecia 53%
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 62.4%
nausea 50.5%
neutropenia 38.6%
NCT02513472 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 30.8%
dyspnea 21.2%
nausea 21.2%
NCT02129556 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 80%
nausea 55%
aspartate aminotransferase increased 40%
NCT03032107 · Phase 1 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab's landscape · Pembrolizumab berahyaluronidase alfa's landscape